Pharmacotherapeutic group: Other antiprotozoal agents
ATCVet code: QP51AX14
Pharmacodynamic properties
Decoquinate is a 4-hydroxyquinoline antiprotozoal compound active against Eimeria spp. and Toxoplasma spp.
Decoquinate inhibits the development of coccidia in the small intestine in the early part of the infective cycle, resulting in lower morbidity and mortality. The exact mode of action is unknown.
Pharmacokinetic particulars
The drug is administered by the oral route, the main site of action being within the gastro-intestinal tract. It is poorly absorbed by the target species and is largely eliminated in faeces unchanged. Consequently, tissue residues are low and deplete rapidly with time. Recovery of the administered material via excretion is essentially complete.